Novel KIAA1061-like cell adhesion molecule-like proteins and polynucleotides encoding them
AssigneeCuraGen Corporation
InventorsElma Fernandes, Corine Vernet, Richard A. Shimkets
Life of this patent
Estimating the term…
Abstract
This application is drawn to novel amino acid sequences for mammalian polypeptides that have sequence similarity to human cell adhesion molecule KIAA1061, and processes for preparing the same. The clone identified has a nucleic acid sequence that is 4000 nucleotides long, contains an open reading frame from nucleotides 408-410 and 2934-2936, and encodes a novel polypeptide that is 842 amino acids long
Claims88
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- a) a mature form of an amino acid sequence chosen from the group consisting of SEQ ID NOs:
- 8, 16, 24, 26, 28 and 30;
- b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 8, 16, 24, 26, 28 and 30, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
- c) an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 8, 16, 24, 26, 28 and 30;
- and
- d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 8, 16, 24, 26, 28 and 30, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed.
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- a) a mature form of an amino acid sequence chosen from the group consisting of SEQ ID NOs:
- 2, 4, 6, 10, 12, 14, 18, 20, and 22;
- and
- b) an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 2, 4, 6, 10, 12, 14, 18, 20, and 22.
An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence of a polypeptide selected from the group consisting of:
- a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 8, 16, 24, 26, 28 and 30;
- b) a mature form of a variant of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 8, 16, 24, 26, 28 and 30, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
- c) an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 8, 16, 24, 26, 28 and 30;
- d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 8, 16, 24, 26, 28 and 30, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
- and
- e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOs:
- 8, 16, 24, 26, 28 and 30;
- or the complement of said nucleic acid molecule.
An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence of a polypeptide selected from the group consisting of:
- a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOs:
- SEQ ID NOs:
- 2, 4, 6, 10, 12, 14, 18, 20, and 22;
- b) an amino acid sequence selected from the group consisting of 2, 4, 6, 10, 12, 14, 18, 20, and 22;
- and
- c) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOs:
- 2, 4, 6, 10, 12, 14, 18, 20, and 22;
- or the complement of said nucleic acid molecule.
The method of claim 40, wherein said subject is a human.
The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a SECX-associated disorder, wherein said therapeutic is selected from the group consisting of a SECX polypeptide, a SECX nucleic acid, and a SECX antibody.
(Amended) An isolated nucleic acid comprising any one of the following:
- (a) a nucleic acid sequence encoding a polypeptide of SEQ ID NO:
- 16;
- (b) a nucleic acid sequence at least 90% identical to the nucleic acid sequence of (a) above;
- (c) a nucleic acid encoding a polypeptide wherein the polypeptide has conservative amino acid substitutions to the polypeptide of SEQ ID NO:
- 16;
- or
- (d) a fragment of the nucleic acid sequence of (a) or (b) above wherein the fragment comprises at least 20 nucleotides.
Dependencies are inferred from the claim text.